Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that preliminary results of a phase II clinical trial to treat leukemia with a WT1 DNA vaccine delivered with Inovio's proprietary electroporation delivery system showed robust vaccine-specific antibody responses in all vaccinated subjects evaluated to date. Furthermore, T cell immune responses, including those of the "killer T cells," were detected. Antibody and T cell responses are strong signals of the DNA vaccine's potential to treat the disease. The data was presented today at an international conference, DNA Vaccines 2012, in San Diego, Ca, by Dr. Christian H. Ottensmeier, MD, PhD, the trial's principal investigator and Professor of Experimental Cancer Research at the University of Southampton, UK. These interim results, from eight patients, are part of a phase II trial that will enroll 31 patients in its chronic myelogenous leukemia (CML) arm. To date, 14 CML patients have been enrolled while another 13 unvaccinated CML patients have been enrolled to serve as a control group. The vaccine has been shown to be safe overall and well-tolerated in the trial subjects. A detailed analysis of T cell immune responses as well as the impact of the vaccination on the molecular marker, BCR-ABL, which is a specific chromosomal abnormality that is associated with chronic myelogenous leukemia (CML) disease, will be performed. As a result of the favorable safety and immunogenicity profiles observed in the CML vaccinated group, the trial is now open to enroll the acute myeloid leukemia (AML) clinical trial arm, with a total target of 37 subjects in each of the vaccinated and control groups. This open-label, multi-center phase II clinical trial is evaluating a DNA vaccine-based immune therapy to treat these two types of leukemia. The DNA vaccine, developed by the University of Southampton, is delivered using Inovio's proprietary electroporation technology. Financial support for the trial is being provided by the UK research charity Leukaemia and Lymphoma Research (LLR) and the Efficacy and Mechanisms Evaluation (EME) programme (which is funded by the UK Medical Research Council and managed by the UK National Institute for Health Research). Leukemia is a cancer of the bone marrow and blood that accounts for at least 300,000 new cases and 222,000 deaths worldwide each year - a very high death rate. Wilms' Tumor gene 1 (WT1) is highly associated with these types of cancer. Preclinical data from mice showed strong induction of antigen-specific CD8+ T cells and the ability to kill human tumor cells expressing WT1. This is the first study to combine DNA vaccination with electroporation delivery of WT1 antigens with the goal of stimulating high and durable levels of immune responses, in particular T cells, which are considered critical for improving clinical outcomes for this disease. The principal investigator of this study, Dr. Ottensmeier, said, "These preliminary data show strong vaccine-induced immune responses in vaccinated subjects in the CML arm. We are looking forward to enrolling and testing the vaccine's impact in AML patients, who currently have limited treatment options and a low rate of progression free survival." In this ongoing phase II trial, all participants initially receive six doses of two DNA vaccines (called p.DOM-WT1-37 and p.DOM-WT1-126) delivered at four week intervals. Vaccine responders may continue with booster vaccinations every three months out to 24 months. An additional 60-75 AML/CML patients are being enrolled across the two arms as non-vaccinated controls for comparison. The primary endpoints are molecular responses to a disease marker called BCR-ABL in CML patients and time to disease progression in AML patients. The study is also monitoring WT1 transcript levels, immune responses to the WT1 antigen, time to progression and overall survival, and two-year survival in the AML group. The trial is taking place at hospitals in Southampton, London and Exeter. Regulatory approval to start this clinical study was provided by the UK Medicines and Healthcare Products Regulatory Authority (MHRA) and Gene Technology Advisory Committee (GTAC). Inovio's CEO, Dr. J. Joseph Kim, said, "We are encouraged by preliminary phase II data showing the WT1 DNA vaccine's potential, administered with our novel delivery technology, to generate T cells and robust antibodies to treat leukemia. These results follow on our recent scientific breakthrough represented by our human data showing the powerful killing effect of T cells generated by our cervical dysplasia therapeutic vaccine.

La camiseta "salvavidas" del Hospital Vírgen Macarena de Sevilla

¿Conoces las Isoflavonas de soja?

Las isoflavonas de soja son un grupo de sustancias vegetales presentes en el grano de la soja, una legumbre consumida tradicionalmente en China, Japón y otros países asiáticos. Un estudio reciente ha demostrado que  las isoflavonas tienen una capacidad antioxidante en el organismo, comparables al de la Vitamina E.
Las isoflavonas ayudan a evitar los problemas de osteoporosis, actúan contra la sequedad vaginal y, principalmente, reducen la frecuencia e intensidad de los sofocos.

¿Qué es la terapia con tecnología Led?

La terapia a base de luz o fototerapia no es algo nuevo en la ciencia. Las plantas convierten dióxido de carbono en azúcar, sustento de la vida, utilizando la energía de la luz solar. En la actualidad se han desarrollado dispositivos con tecnología LED que se aplican directamente en la zona a tratar, especialmente en su primera fase.
Estos dispositivos emiten una luz terapéutica, que es absorbida por las células de la piel, estimulando el proceso natural del cuerpo para atacar los virus, en el caso del herpes, o las bacterias en el caso del acné. Estas células, ahora "más eficientes", repararan el deterioro provocado en un período de tiempo más corto y previenen la aparición de nuevos brotes.

-¿Para qué se utiliza en belleza?
Actualmente, se está utilizando con éxito para combatir las calenturas del herpes labial, los granos y espinillas del acné.

¿Cuándo es recomendable recurrir a las enzimas digestivas?

** Con las digestiones pesadas

**Con problemas para digerir la lactosa( leche, yoghurt, queso, etc)

**Con problemas para digerir el gluten( pan, pizza, pasta, etc)

**Con alteraciones para el metabolismo lipídico

¿Qué hacen los probióticos en nuestro organismo?

Actúan a nivel del tubo digestivo. Por una parte ayudan a regular la flora bacteriana. Cuando los probióticos pasan al estómago se adhieren a las paredes del aparato digestivo, evitando así que lo hagan las bacterias nocivas.
Por otro lado, incrementan la respuesta del sistema inmunológico ante diversos agentes agresores. Como consecuencia ayudan a reforzar las defensas, a mejoras la digestión y a recuperar el equilibrio de la flora intestinal.

RUNTASTIC y HEAD se unen para desarrollar el primer casco en el mundo totalmente integrado para deportes de invierno: el HEAD SENSOR BT RUNTASTIC

Runtastic lanzará al mercado este domingo 9 de diciembre un casco para esquiar o practicar snowboard único en su tipo que integra la runtastic app, bluetooth, altavoces, micrófono en el galadornado diseño de HEAD, empresa líder en desarrollo de equipo de deportes de invierno.
El casco y la runtastic app te dicen velocidad, altitud, distancia recorrida, ruta, velocidad, ritmo cardíaco, calorías; se pueden compartir estadísticas deportivas y experiencias en tiempo real en las redes sociales, además de interactuar con amigos, puedes escuchar tu música favorita y hasta llamar a tus amigos por teléfono con comandos de voz.